Neurorehabilitation News

CHICAGO — The neurological pathology of COVID-19 becomes more complex as symptoms persist and tends to affect the central nervous system more prominently, according to an expert at the American Neurological Association annual meeting.

CHICAGO – Felicia Chow, MD, MAS, a neuro-infectious specialist at the University of California, San Francisco, discussed the care and approach to neurological infections during a panel at ANA 2022.

Reata Pharmaceuticals Inc. announced the FDA does not plan to hold an advisory committee meeting to discuss the company’s new drug application for an investigational therapeutic to treat Friedreich’s ataxia.

MediCane Health Inc. announced recruitment of the first patient for its phase 2a study designed to assess the effects of cannabis oil in adults with probable Alzheimer’s disease who have limited or no response to antipsychotic medication.

Daily treatment with risdiplam over 24 months resulted in improved motor function and achievement of developmental motor milestones in infants with type 1 spinal muscular atrophy, according to a study published in The Lancet Neurology.

Empyrean Neuroscience Inc. has announced its launch as a genetic engineering company dedicated to developing fungi- and plant-based therapeutics for the treatment of neuropsychiatric and neurologic disorders.

The FDA has granted breakthrough device designation to neurotechnology company Axoft for its brain-machine interface to treat long-term neurological disorders.

A Tulane University neurosurgeon is among the first to perform a procedure with Minnetronix Medical’s MindsEye expandable port, a minimally invasive device for surgical treatment of stroke, cancer and other neurological conditions.

Antidepressant use in pregnancy was not associated with neurodevelopmental disorders in offspring, according to a cohort study published in JAMA Internal Medicine.

The National Football League and the NFL Players Association have issued a joint statement finalizing review of the league’s concussion protocol, which now prohibits a player from returning to a game if diagnosed with ataxia.